Rigel Pharmaceuticals (RIGL) Depreciation & Amortization (CF) (2016 - 2025)
Historic Depreciation & Amortization (CF) for Rigel Pharmaceuticals (RIGL) over the last 17 years, with Q3 2025 value amounting to $603000.0.
- Rigel Pharmaceuticals' Depreciation & Amortization (CF) fell 130.93% to $603000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.4 million, marking a year-over-year increase of 2613.46%. This contributed to the annual value of $2.2 million for FY2024, which is 7996.77% up from last year.
- Per Rigel Pharmaceuticals' latest filing, its Depreciation & Amortization (CF) stood at $603000.0 for Q3 2025, which was down 130.93% from $607000.0 recorded in Q2 2025.
- In the past 5 years, Rigel Pharmaceuticals' Depreciation & Amortization (CF) registered a high of $613000.0 during Q2 2024, and its lowest value of $237000.0 during Q1 2022.
- In the last 5 years, Rigel Pharmaceuticals' Depreciation & Amortization (CF) had a median value of $296000.0 in 2023 and averaged $391578.9.
- Its Depreciation & Amortization (CF) has fluctuated over the past 5 years, first plummeted by 2970.3% in 2022, then skyrocketed by 10924.66% in 2024.
- Rigel Pharmaceuticals' Depreciation & Amortization (CF) (Quarter) stood at $404000.0 in 2021, then dropped by 29.7% to $284000.0 in 2022, then increased by 3.17% to $293000.0 in 2023, then surged by 106.14% to $604000.0 in 2024, then dropped by 0.17% to $603000.0 in 2025.
- Its Depreciation & Amortization (CF) stands at $603000.0 for Q3 2025, versus $607000.0 for Q2 2025 and $604000.0 for Q1 2025.